Abstract
Vitamin D receptor (VDR) modulators are used to treat hyperparathyroidism secondary to chronic kidney disease (CKD). The therapy is associated with reduced mortality in stage 5 CKD patients, who experience an extremely high cardiovascular disease (CVD)-related mortality rate. Chen et al. report that VDR is involved in regulating type A natriuretic peptide receptor (NPR-A) in inner medullary collecting duct cells. The regulation of NPR-A may be one of several mechanisms by which VDR activation reduces CVD risk in CKD.
MeSH terms
-
25-Hydroxyvitamin D3 1-alpha-Hydroxylase / metabolism
-
Animals
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / physiopathology
-
Chronic Disease
-
Guanylate Cyclase / metabolism*
-
Humans
-
Kidney Diseases / complications
-
Kidney Diseases / physiopathology
-
Mice
-
Mice, Knockout
-
Rats
-
Receptors, Atrial Natriuretic Factor / metabolism*
-
Receptors, Calcitriol / genetics
-
Receptors, Calcitriol / physiology*
-
Receptors, Cytoplasmic and Nuclear / physiology*
Substances
-
Receptors, Calcitriol
-
Receptors, Cytoplasmic and Nuclear
-
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
-
Guanylate Cyclase
-
Receptors, Atrial Natriuretic Factor
-
atrial natriuretic factor receptor A